Cargando…
Ex Vivo Fluorescence Confocal Microscopy (FCM) Ensures Representative Tissue in Prostate Cancer Biobanking: A Feasibility Study
Background: Biobanking of prostate carcinoma is particularly challenging due to the actual cancer within the organ often without clear margins. Frozen sections are to date the only way to examine the biobank material for its tumor content. We used ex vivo fluorescence confocal microscopy (FCM) to an...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603154/ https://www.ncbi.nlm.nih.gov/pubmed/36292970 http://dx.doi.org/10.3390/ijms232012103 |
_version_ | 1784817477959548928 |
---|---|
author | Titze, Ulf Sommerkamp, Johannes Stege, Clara Schneider, Fried Brochhausen, Christoph Schulz, Birte Titze, Barbara Abd Ali, Furat Pokupic, Sasa Sievert, Karl-Dietrich Hansen, Torsten |
author_facet | Titze, Ulf Sommerkamp, Johannes Stege, Clara Schneider, Fried Brochhausen, Christoph Schulz, Birte Titze, Barbara Abd Ali, Furat Pokupic, Sasa Sievert, Karl-Dietrich Hansen, Torsten |
author_sort | Titze, Ulf |
collection | PubMed |
description | Background: Biobanking of prostate carcinoma is particularly challenging due to the actual cancer within the organ often without clear margins. Frozen sections are to date the only way to examine the biobank material for its tumor content. We used ex vivo fluorescence confocal microscopy (FCM) to analyze biobank samples prior to cryoasservation. Methods: 127 punch biopsies were acquired from prostatectomy-specimens from 40 patients. These biopsies were analyzed with a Vivascope 2500-G4 prior to their transfer to the biobank. In difficult cases, larger samples of the prostatectomy specimens were FCM scanned in order to locate tumor foci. After patient acquisition, all samples were taken from the biobank and analyzed. We compared the results of the FCM examinations with the results of conventional histology and measured the DNA content. Results: With upstream FCM, the tumor content of biobank samples could be determined with high confidence. The detection rate of representative biobank samples was increased due to the rapid feedback. The biobank samples were suitable for further molecular analysis. Conclusion: FCM allows for the first time lossless microscopic analysis of biobank samples prior to their cryoasservation and guarantees representative tumor and normal tissue for further molecular analysis. |
format | Online Article Text |
id | pubmed-9603154 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96031542022-10-27 Ex Vivo Fluorescence Confocal Microscopy (FCM) Ensures Representative Tissue in Prostate Cancer Biobanking: A Feasibility Study Titze, Ulf Sommerkamp, Johannes Stege, Clara Schneider, Fried Brochhausen, Christoph Schulz, Birte Titze, Barbara Abd Ali, Furat Pokupic, Sasa Sievert, Karl-Dietrich Hansen, Torsten Int J Mol Sci Article Background: Biobanking of prostate carcinoma is particularly challenging due to the actual cancer within the organ often without clear margins. Frozen sections are to date the only way to examine the biobank material for its tumor content. We used ex vivo fluorescence confocal microscopy (FCM) to analyze biobank samples prior to cryoasservation. Methods: 127 punch biopsies were acquired from prostatectomy-specimens from 40 patients. These biopsies were analyzed with a Vivascope 2500-G4 prior to their transfer to the biobank. In difficult cases, larger samples of the prostatectomy specimens were FCM scanned in order to locate tumor foci. After patient acquisition, all samples were taken from the biobank and analyzed. We compared the results of the FCM examinations with the results of conventional histology and measured the DNA content. Results: With upstream FCM, the tumor content of biobank samples could be determined with high confidence. The detection rate of representative biobank samples was increased due to the rapid feedback. The biobank samples were suitable for further molecular analysis. Conclusion: FCM allows for the first time lossless microscopic analysis of biobank samples prior to their cryoasservation and guarantees representative tumor and normal tissue for further molecular analysis. MDPI 2022-10-11 /pmc/articles/PMC9603154/ /pubmed/36292970 http://dx.doi.org/10.3390/ijms232012103 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Titze, Ulf Sommerkamp, Johannes Stege, Clara Schneider, Fried Brochhausen, Christoph Schulz, Birte Titze, Barbara Abd Ali, Furat Pokupic, Sasa Sievert, Karl-Dietrich Hansen, Torsten Ex Vivo Fluorescence Confocal Microscopy (FCM) Ensures Representative Tissue in Prostate Cancer Biobanking: A Feasibility Study |
title | Ex Vivo Fluorescence Confocal Microscopy (FCM) Ensures Representative Tissue in Prostate Cancer Biobanking: A Feasibility Study |
title_full | Ex Vivo Fluorescence Confocal Microscopy (FCM) Ensures Representative Tissue in Prostate Cancer Biobanking: A Feasibility Study |
title_fullStr | Ex Vivo Fluorescence Confocal Microscopy (FCM) Ensures Representative Tissue in Prostate Cancer Biobanking: A Feasibility Study |
title_full_unstemmed | Ex Vivo Fluorescence Confocal Microscopy (FCM) Ensures Representative Tissue in Prostate Cancer Biobanking: A Feasibility Study |
title_short | Ex Vivo Fluorescence Confocal Microscopy (FCM) Ensures Representative Tissue in Prostate Cancer Biobanking: A Feasibility Study |
title_sort | ex vivo fluorescence confocal microscopy (fcm) ensures representative tissue in prostate cancer biobanking: a feasibility study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603154/ https://www.ncbi.nlm.nih.gov/pubmed/36292970 http://dx.doi.org/10.3390/ijms232012103 |
work_keys_str_mv | AT titzeulf exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy AT sommerkampjohannes exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy AT stegeclara exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy AT schneiderfried exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy AT brochhausenchristoph exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy AT schulzbirte exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy AT titzebarbara exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy AT abdalifurat exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy AT pokupicsasa exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy AT sievertkarldietrich exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy AT hansentorsten exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy |